TISIDB

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endomembrane system Peripheral membrane protein Cytoplasm
Domain	PF07714 Protein tyrosine kinase
Function	Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.

> Gene Ontology [ TOP ]
Biological Process	GO:0001776 leukocyte homeostasis GO:0001818 negative regulation of cytokine production GO:0002250 adaptive immune response GO:0002260 lymphocyte homeostasis GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002287 alpha-beta T cell activation involved in immune response GO:0002292 T cell differentiation involved in immune response GO:0002293 alpha-beta T cell differentiation involved in immune response GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002367 cytokine production involved in immune response GO:0002371 dendritic cell cytokine production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002695 negative regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002698 negative regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002701 negative regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002704 negative regulation of leukocyte mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002719 negative regulation of cytokine production involved in immune response GO:0002730 regulation of dendritic cell cytokine production GO:0002731 negative regulation of dendritic cell cytokine production GO:0002819 regulation of adaptive immune response GO:0002820 negative regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002825 regulation of T-helper 1 type immune response GO:0002826 negative regulation of T-helper 1 type immune response GO:0006606 protein import into nucleus GO:0006913 nucleocytoplasmic transport GO:0007159 leukocyte cell-cell adhesion GO:0007162 negative regulation of cell adhesion GO:0007259 JAK-STAT cascade GO:0007260 tyrosine phosphorylation of STAT protein GO:0007262 STAT protein import into nucleus GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0010559 regulation of glycoprotein biosynthetic process GO:0010561 negative regulation of glycoprotein biosynthetic process GO:0017038 protein import GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030183 B cell differentiation GO:0030217 T cell differentiation GO:0032613 interleukin-10 production GO:0032615 interleukin-12 production GO:0032653 regulation of interleukin-10 production GO:0032655 regulation of interleukin-12 production GO:0032693 negative regulation of interleukin-10 production GO:0032695 negative regulation of interleukin-12 production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0034504 protein localization to nucleus GO:0035710 CD4-positive, alpha-beta T cell activation GO:0035771 interleukin-4-mediated signaling pathway GO:0038083 peptidyl-tyrosine autophosphorylation GO:0042088 T-helper 1 type immune response GO:0042093 T-helper cell differentiation GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042110 T cell activation GO:0042113 B cell activation GO:0042129 regulation of T cell proliferation GO:0043029 T cell homeostasis GO:0043367 CD4-positive, alpha-beta T cell differentiation GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043434 response to peptide hormone GO:0044744 protein targeting to nucleus GO:0045063 T-helper 1 cell differentiation GO:0045210 FasL biosynthetic process GO:0045219 regulation of FasL biosynthetic process GO:0045221 negative regulation of FasL biosynthetic process GO:0045580 regulation of T cell differentiation GO:0045581 negative regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045620 negative regulation of lymphocyte differentiation GO:0045622 regulation of T-helper cell differentiation GO:0045623 negative regulation of T-helper cell differentiation GO:0045625 regulation of T-helper 1 cell differentiation GO:0045626 negative regulation of T-helper 1 cell differentiation GO:0045785 positive regulation of cell adhesion GO:0046631 alpha-beta T cell activation GO:0046632 alpha-beta T cell differentiation GO:0046634 regulation of alpha-beta T cell activation GO:0046636 negative regulation of alpha-beta T cell activation GO:0046637 regulation of alpha-beta T cell differentiation GO:0046639 negative regulation of alpha-beta T cell differentiation GO:0046651 lymphocyte proliferation GO:0046777 protein autophosphorylation GO:0048872 homeostasis of number of cells GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050777 negative regulation of immune response GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050866 negative regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050868 negative regulation of T cell activation GO:0050870 positive regulation of T cell activation GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051249 regulation of lymphocyte activation GO:0051250 negative regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0060396 growth hormone receptor signaling pathway GO:0060397 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060416 response to growth hormone GO:0070227 lymphocyte apoptotic process GO:0070228 regulation of lymphocyte apoptotic process GO:0070229 negative regulation of lymphocyte apoptotic process GO:0070231 T cell apoptotic process GO:0070232 regulation of T cell apoptotic process GO:0070233 negative regulation of T cell apoptotic process GO:0070242 thymocyte apoptotic process GO:0070243 regulation of thymocyte apoptotic process GO:0070244 negative regulation of thymocyte apoptotic process GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0070669 response to interleukin-2 GO:0070670 response to interleukin-4 GO:0070672 response to interleukin-15 GO:0071104 response to interleukin-9 GO:0071353 cellular response to interleukin-4 GO:0071375 cellular response to peptide hormone stimulus GO:0071378 cellular response to growth hormone stimulus GO:0071417 cellular response to organonitrogen compound GO:0071593 lymphocyte aggregation GO:0071887 leukocyte apoptotic process GO:0097696 STAT cascade GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1902105 regulation of leukocyte differentiation GO:1902106 negative regulation of leukocyte differentiation GO:1902593 single-organism nuclear import GO:1903018 regulation of glycoprotein metabolic process GO:1903019 negative regulation of glycoprotein metabolic process GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903038 negative regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903706 regulation of hemopoiesis GO:1903707 negative regulation of hemopoiesis GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000514 regulation of CD4-positive, alpha-beta T cell activation GO:2000515 negative regulation of CD4-positive, alpha-beta T cell activation
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004715 non-membrane spanning protein tyrosine kinase activity GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding
Cellular Component	GO:0009898 cytoplasmic side of plasma membrane GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0031234 extrinsic component of cytoplasmic side of plasma membrane GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04062 Chemokine signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04630 Jak-STAT signaling pathway
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-186763: Downstream signal transduction R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-392451: G beta R-HSA-397795: G-protein beta R-HSA-388396: GPCR downstream signaling R-HSA-114604: GPVI-mediated activation cascade R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-1266695: Interleukin-7 signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04062 Chemokine signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04630 Jak-STAT signaling pathway

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between JAK3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between JAK3 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26014096	Lung Carcinoma	Inhibit immunity (T cell function)	We discovered activating somatic and germline amino acid variants in JAK3 that promoted PD-L1 induction in lung cancer cells and in the tumor immune microenvironment.
22588558	Nasopharyngeal Carcinoma	Inhibit immunity	In epithelial cells, LMP1 up-regulated HLA class I APM. This effect could be counteracted by c-Myc, which itself was up-regulated by LMP1 apparently through IL6 induction and Jak3/STAT3 activation. These findings raise the possibility that c-Myc activation in nasopharyngeal carcinoma (NPC) might antagonise the effect of LMP1 on HLA class I expression thus contributing to immune escape of tumour cells.
18281483	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Inhibit immunity (T and NK cell function); immunotherapy target	They also suggest two novel therapeutic approaches to CTCL and, possibly, other CD4+ T-cell lymphomas: inhibition of the Jak1/Jak3 kinase complex and, given the known strong immunostimulatory properties of IL-21 on CD8+ T, natural killer, and B cells, application of this cytokine to boost an immune response against malignant CD4+ T cells.
25125657	melanoma	Promote immunity	Mechanistically, in CD8(+) T cells, exposure to CCDC134 promoted cell proliferation through the JAK3-STAT5 pathway, a classic feature of many cytokines of the common gamma-chain (gamma(c)) cytokine receptor family.

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of JAK3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of JAK3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.425	0.405
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.074	0.388
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.04	0.971
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.514	0.257
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.269	0.897
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.83	0.766
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.858	0.0943
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.028	0.433
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.796	0.547
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.4	0.207
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.324	0.419
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.171	0.293

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of JAK3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JAK3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JAK3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JAK3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JAK3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of JAK3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between JAK3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	JAK3
Name	Janus kinase 3
Aliases	L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location	19p13-p12
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting JAK3 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting JAK3.

ID	Name	Drug Type	Targets	#Targets
DB04716	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE	Small Molecule	DAPK3, JAK1, JAK2, JAK3, TYK2	5
DB08895	Tofacitinib	Small Molecule	JAK1, JAK2, JAK3, TYK2	4
DB11817	Baricitinib	Small Molecule	JAK1, JAK2, JAK3, PTK2B	4

Browse JAK3